Skip to main
HOWL
HOWL logo

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics is positioned favorably due to its innovative approach in developing therapeutics that stimulate the immune system for cancer treatment, utilizing its proprietary PREDATOR platform to create conditionally activated molecules. The company's ability to selectively activate INDUKINE molecules in the tumor microenvironment is pivotal, potentially overcoming limitations inherent in conventional immune therapies. This strategic focus on advanced immunotherapy not only aligns with current market trends toward personalized medicine but also highlights Werewolf's potential for significant growth in a competitive biopharmaceutical landscape.

Bears say

Werewolf Therapeutics Inc. faces a challenging financial environment as indicated by the downward revision of full-year same-store revenue growth, which has been adjusted from a range of (0.35%)-1.15% to a new range of (0.20%)-0.40%. Additionally, the company reported a 30 basis points year-over-year decline in revenues alongside a 3.8% increase in expenses, leading to a 2.6% decrease in net operating income (NOI). Compounding these issues, the average effective rental rate has decreased by 50 basis points year-over-year, highlighting difficulties in maintaining revenue streams from new leases.

Werewolf Therapeutics (HOWL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 4 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.